达匹韦林阴道环试验中血清阳转女性的临床表现、治疗反应与病毒学结局——Ring研究与DREAM研究
在达匹韦林阴道环(DVR)3期试验Ring研究及其开放标签扩展试验DREAM中发生HIV血清阳转的参与者被纳入观察性队列IPM 007,按国家指南接受抗逆转录病毒治疗(ART)。随访12个月时DVR使用组与安慰剂组的HIV-1 RNA和CD4+ T细胞计数相似;ART启动约6个月后,59/78(75.6%)实现HIV-1 RNA<40 copies/mL。病毒学失败时的基因型模式符合基于非核苷类逆转录酶抑制剂(NNRTI)方案的预期。
要点
- DVR使用期间血清阳转未对临床表现或治疗结局产生负面影响。
- ART启动约6个月后,59/78(75.6%)参与者HIV-1 RNA<40 copies/mL。
- 病毒学失败时的突变模式与NNRTI方案失败者一致。
核心结论
- DVR使用期间发生血清阳转未对临床表现或治疗结局产生负面影响。
- 病毒学失败时的突变模式与基于NNRTI方案治疗失败者一致。
研究设计与样本
- Ring研究(DVR 3期试验)和DREAM研究(开放标签扩展试验)中HIV血清阳转的参与者被纳入观察性队列研究IPM 007。
- 参与者HIV感染在当地治疗诊所按国家治疗指南管理。
- IPM 007研究访视在入组后3个月和6个月进行,此后每6个月一次。
- 评估包括血浆HIV-1 RNA、CD4+ T细胞计数,并记录HIV/AIDS相关事件和抗逆转录病毒药物使用。
- 对病毒学失败参与者进行事后病毒学分析。
主要发现
- 179例合格参与者中151例(84.4%)入组IPM 007;103例曾在Ring或DREAM研究中使用DVR,48例在Ring研究中使用安慰剂。
- 随访12个月后,Ring研究和DREAM中使用DVR的参与者与使用安慰剂的参与者HIV-1 RNA和CD4+ T细胞计数相似。
- 在ART启动约6个月后有研究访视的78例参与者中,59例(75.6%)HIV-1 RNA<40 copies/mL(Ring研究:安慰剂组13/23[56.5%];DVR组32/39[82.1%];DREAM[DVR]14/16[87.5%])。
- 事后病毒学分析表明,病毒学失败时观察到的基因型模式符合基于NNRTI方案的预期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Participants with human immunodeficiency virus (HIV) seroconversion in The Ring Study, a phase 3 trial of dapivirine vaginal ring (DVR), or in the open-label extension trial dapivirine ring extended access and monitoring (DREAM) were offered enrollment in an observational cohort study (IPM 007) to assess clinical presentation and response to antiretroviral therapy (ART). METHODS: Participants' HIV infection was managed at local treatment clinics according to national treatment guidelines. IPM 007 study visits occurred 3 and 6 months after enrollment and every 6 months thereafter. Assessments included plasma HIV-1 RNA, CD4+ T-cell counts, and recording of HIV/AIDS-associated events and antiretroviral use. Post hoc virology analyses were performed for participants identified with virologic failure. RESULTS: One hundred fifty-one of 179 eligible participants (84.4%) enrolled into IPM 007; 103 had previously received the DVR in the Ring or DREAM studies, and 48 had received placebo in The Ring Study. HIV-1 RNA and CD4+ T-cell counts after 12 months' follow-up were similar for participants who used the DVR in The Ring Study and DREAM, compared to those who received placebo. Of the 78 participants with a study visit approximately 6 months after ART initiation, 59 (75.6%) had HIV-1 RNA <40 copies/mL (The Ring Study: placebo: 13/23 [56.5%]; DVR: 32/39 [82.1%]; DREAM [DVR]: 14/16 [87.5%]). Post hoc virology analysis indicated that genotypic patterns observed at virologic failure were as expected of a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. CONCLUSIONS: Seroconversion during DVR use did not negatively affect clinical presentation or treatment outcome. Mutation patterns at virologic failure were in line with individuals failing an NNRTI-based regimen. CLINICAL TRIALS REGISTRATION: NCT01618058.
引用
- Steytler J, van der Ryst E, Craig C, et al. Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials-The Ring Study and DREAM. Clin Infect Dis. 2023. PMID: 36189636. doi:10.1093/cid/ciac804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。